Nesina

Physical Activity, Type 2 Diabetes, Diet

Treatment

4 FDA approvals

20 Active Studies for Nesina

What is Nesina

Alogliptin

The Generic name of this drug

Treatment Summary

Alogliptin is an oral medication that helps control blood sugar levels by inhibiting the activity of the enzyme dipeptidyl peptidase-4 (DPP-4). It is available as a benzoate salt and is mainly composed of the R-enantiomer. Alogliptin was approved by the FDA in 2013 and does not convert to the S-enantiomer when taken.

Nesina

is the brand name

image of different drug pills on a surface

Nesina Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nesina

Alogliptin

2013

26

Approved as Treatment by the FDA

Alogliptin, also known as Nesina, is approved by the FDA for 4 uses which include Type 2 Diabetes and Type 2 Diabetes Mellitus .

Type 2 Diabetes

Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone

Type 2 Diabetes Mellitus

Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone

Physical Activity

Used to treat Exercise in combination with Pioglitazone

Diet

Used to treat Diet in combination with Pioglitazone

Effectiveness

How Nesina Affects Patients

Alogliptin starts to reduce the levels of an enzyme (DPP-4) within 2-3 hours after being taken, and it continues to keep levels low for up to 24 hours with doses of 25 mg or higher. It also helps to lower glucagon and increase levels of a hormone (GLP-1) that helps regulate blood sugar levels. Taking alogliptin will not affect the time it takes for your heart to beat.

How Nesina works in the body

Alogliptin helps control blood sugar levels by blocking an enzyme called dipeptidyl peptidase 4 (DPP-4). This enzyme usually breaks down the hormones GIP and GLP-1, which stimulate insulin production. Alogliptin prevents this breakdown, so more of these hormones are in the blood. This increases insulin production, suppresses glucagon production, and helps with feelings of fullness.

When to interrupt dosage

The amount of Nesina is contingent upon the established affliction, including Diet, Physical Activity and Type 2 Diabetes. The dosage is subject to the mode of delivery (as outlined in the table below).

Condition

Dosage

Administration

Diet

, 6.25 mg, 12.5 mg, 25.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Type 2 Diabetes

, 6.25 mg, 12.5 mg, 25.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Physical Activity

, 6.25 mg, 12.5 mg, 25.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Nesina.

Common Nesina Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Alogliptin.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Alogliptin.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Alogliptin.

Clomipramine

Major

The metabolism of Clomipramine can be decreased when combined with Alogliptin.

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Alogliptin.

Nesina Toxicity & Overdose Risk

Alogliptin overdose may lead to common side effects such as a sore throat, headache, and respiratory infection. These symptoms occur in at least 4% of those who take alogliptin and more often than in those taking a placebo.

Nesina Novel Uses: Which Conditions Have a Clinical Trial Featuring Nesina?

196 active studies are in progress to assess the potential of Nesina for improving Physical Activity, managing Type 2 Diabetes and providing Dietary benefits.

Condition

Clinical Trials

Trial Phases

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Physical Activity

30 Actively Recruiting

Not Applicable, Phase 2

Type 2 Diabetes

185 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1, Phase 3

Nesina Reviews: What are patients saying about Nesina?

5

Patient Review

11/11/2013

Nesina for Type 2 Diabetes Mellitus

This medication has been extremely effective for me. I take it along with a low dose of Amaryl each day, and my A1C level has dropped from 7.3 to 5.9 in just three months!

1

Patient Review

9/13/2016

Nesina for Type 2 Diabetes Mellitus

After taking Januvia for many years, my insurance company made me switch to Nesina. My blood sugar has been spiking since I started taking it, and I've already switched back to Januvia at my own expense.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nesina

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the medication Nesina used for?

"An injectable medication, Alogliptin is used to help manage blood sugar levels in people with type 2 diabetes. When combined with a proper diet and exercise regimen, this medication can help to prevent the onset of serious complications from diabetes, such as kidney damage, blindness, nerve problems, loss of limbs, and sexual dysfunction."

Answered by AI

Does Nesina have metformin in it?

"The drugs in Nesina Met are alogliptin and metformin hydrochloride. Alogliptin is given in a dose of 12.5 mg per 1000 mg metformin hydrochloride."

Answered by AI

What is the difference between Januvia and Nesina?

"If you're struggling to get your blood sugar under control, Januvia (sitagliptin) could be a good addition to your treatment plan. Januvia lowers blood sugar levels and is taken orally, so you don't have to worry about injections. Nesina (alogliptin) is another option for oral treatment, but it's not as effective as Januvia."

Answered by AI

Does Nesina cause weight gain?

"Nesina will not make you gain weight. It helps the body to produce more insulin when blood sugar is high, and also tells the liver to reduce sugar production."

Answered by AI

Clinical Trials for Nesina

Image of University of Cincinnati Medical Center in Cincinnati, United States.

Continuous Glucose Monitoring for Type 2 Diabetes

18+
All Sexes
Cincinnati, OH

The TRANSITION-CGM trial will evaluate whether starting continuous glucose monitoring (CGM) before hospital discharge improves blood glucose control in adults with type 2 diabetes compared with usual care using finger-stick blood glucose checks. The study focuses on the transition from hospital to home, when patients may face changes in diabetes medications and challenges managing their blood glucose levels. This single-center, randomized controlled trial will enroll approximately 218 adults with type 2 diabetes, a hemoglobin A1c (HbA1c) 9% and above, and treatment with insulin and/or oral diabetes medications. Participants will be recruited during hospitalization and must be expected to return home after discharge. People already using a CGM will not be eligible. Participants will be randomly assigned in equal numbers to one of two groups. The CGM group will start using a continuous glucose monitor before discharge and receive device training and written instructions. The usual-care group will continue finger-stick blood glucose monitoring and receive standard discharge education. Both groups will receive assistance with outpatient diabetes follow-up. Diabetes medications will be managed by treating clinicians according to usual clinical practice. Participants will be followed for approximately 12 weeks after discharge, with an early follow-up encounter and a final assessment at 12 weeks. The primary outcome is HbA1c at 12 weeks, a blood test that reflects average blood glucose levels over approximately three months. Secondary outcomes include diabetes-related hospitalizations and episodes of low blood sugar. Additional exploratory measures include CGM use, follow-up attendance, patient-reported experiences, and time spent within the target glucose range when CGM data are available. The study will determine whether initiating CGM during hospitalization can improve glycemic control after discharge and provide preliminary evidence about its effects on diabetes-related hospitalizations and hypoglycemia.

Waitlist Available
Has No Placebo

University of Cincinnati Medical Center

Arunab H Mehta, MD, MEd

Have you considered Nesina clinical trials?

We made a collection of clinical trials featuring Nesina, we think they might fit your search criteria.
Go to Trials
Image of Penn Medicine, 3535 Market St. in Philadelphia, United States.

Financial Counseling and Health Reviews for Chronic Illness Management

18+
All Sexes
Philadelphia, PA

Among adults with chronic illnesses like hypertension, diabetes, or HIV, adherence to daily oral medications is essential but often below 50%. Why do medication adherence and preventive health service engagement remain stubbornly low? Scarcity theory offers a novel explanation in the context of poverty. It posits that economic hardship imposes a cognitive burden that shifts attention from long-term goals to immediate needs, reduces future orientation (the relative value placed on immediate vs. future outcomes), and limits mental bandwidth (the cognitive resources needed for decisions), thus undermining behaviors like daily medication adherence and service engagement. To address these gaps, the study's objective is to rigorously test whether and how economic scarcity affects medication adherence and preventive service uptake among older adults with chronic disease, leveraging the naturally occurring monthly fluctuation in scarcity created by the Supplemental Nutrition Assistance Program (SNAP) benefit cycle as a natural experiment. There are three aims: 1. Daily medication adherence will be measured objectively for four months with wireless electronic pill bottle caps (CleverCaps). The investigators will test whether, when, and by how much adherence changes as scarcity fluctuates during the SNAP benefit cycle. 2. The investigators will conduct two easily implementable RCTs to test whether scarcity affects participants' engagement with beneficial services requiring navigation of administrative burdens. In one trial, participants will be randomized to receive an invitation during either a high- or low- scarcity period (i.e., before vs. after SNAP receipt) to a personalized preventive health review that identifies gaps in US Preventive Services Task Force Grade A/B recommendations. In the second, participants will be invited to free financial counseling provided by the City of Philadelphia during a high- or low-scarcity period. The investigators hypothesize invitation response rates will be \>15% higher during low-scarcity periods. 3. Potential mechanisms that link scarcity with health behaviors will be examined by randomizing timing of validated measures of mental bandwidth and future orientation during a period of high- or low-scarcity (i.e., before vs. after SNAP receipt). The investigators hypothesize that there will be differences in several measures between participants who are randomly assessed during high- vs. low-scarcity periods (i.e. before vs. after SNAP receipt). Impact: Demonstrating that scarcity helps to explain low medication adherence and beneficial health-related service uptake can inform patient-centered adherence interventions, clinical care-delivery approaches, health-system strategies, and public health approaches to improve these health behaviors and promote healthy aging.

Waitlist Available
Has No Placebo

Penn Medicine, 3535 Market St.

Image of Lake Havasu Unified School District in Lake Havasu City, United States.

Nutrition and Fitness Program for Schoolchildren's Health

9 - 14
All Sexes
Lake Havasu City, AZ

The goal of this clinical trial is to learn if a school-based intervention, Operation ToneUp, can improve nutrition knowledge, fitness, and blood pressure in schoolchildren enrolled in grades 3-6. The main questions it aims to answer are: 1. Do students participating in the intervention show improved fitness, measured by upper body strength, core strength, and cardiovascular endurance? 2. Do students participating in the intervention show improved nutrition knowledge, measured by self-report? 3. Do students participating in the intervention show improved blood pressure, measured by blood pressure cuff? Researchers will compare students participating in the intervention to students at comparison schools to see if fitness, nutrition knowledge, and blood pressure differ. Participants in the intervention arm will complete two 20-minute web-based sessions focused on nutrition and fitness during class time. Participants in the comparison arm will not be exposed to Operation ToneUp. All participants will engage in pre- and post- testing including: * PE-teacher assessed push-ups, curl-ups, and PACER test * online self-reported nutrition knowledge assessments * nurse-recorded blood pressure

Waitlist Available
Has No Placebo

Lake Havasu Unified School District

Allison Poulos, PhD

Have you considered Nesina clinical trials?

We made a collection of clinical trials featuring Nesina, we think they might fit your search criteria.
Go to Trials
Image of Seva Food Bank in Mississauga, Canada.

Educational Video for Type 2 Diabetes Risk Reduction

Any Age
All Sexes
Mississauga, Canada

The goal of this clinical trial is to assess the potential benefits of integrating a video covering topics related to nutrition education, food literacy and type 2 diabetes into Seva Food Banks current programs (Culinary Training for Youth, Culinary Training for Newcomers, Cooking Classes for Seniors), to learn if integrating this video can reduce risk of type 2 diabetes by improving diet quality, nutrition knowledge, attitudes, and behaviors among participants of the programs. The main question it aims to answer is: How does the integration of a nutrition education video covering topics related to food literacy and type 2 diabetes within Seva Food Bank's Culinary Training programs for youth, newcomers, and seniors influence participants' diet quality, nutrition knowledge, attitudes, and behaviors? Participants will: * Complete a baseline questionnaire before watching the educational video * Watch the nutrition education video * Complete a questionnaire at 2-weeks and again 1-month post-intervention to assess sustained effects and maintenance.

Recruiting
Has No Placebo

Seva Food Bank

Image of Columbia University Irving Medical Center in New York, United States.

Alpelisib for Insulin Resistance

18 - 70
All Sexes
New York, NY

The goal of this study is to test a potentially easier method for measuring how much insulin a person is capable of producing than the current gold-standard method, the "hyperglycemic clamp." Participants will come in for a two-day (overnight) visit in which they will first undergo a "hyperglycemic clamp," in which they receive an intravenous (into the vein) infusion of glucose (sugar) in order to measure the maximum amount of insulin their body produces in response. They will then consume a series of three standardized meals throughout the rest of the day. At 23:00, they will take a single dose of alpelisib, a drug that interferes within insulin's actions in the body. Then, the following morning, they will undergo a "Mixed Meal Tolerance Test" in which they consume a standardized liquid nutritional beverage and have blood drawn periodically before and during the test.

Phase 1
Recruiting

Columbia University Irving Medical Center

Joshua R Cook, MD, PhD

Image of Vanderbilt University Medical Center in Nashville, United States.

Calcium-HMB + Vitamin D for Muscle Loss in Older Adults

65 - 85
All Sexes
Nashville, TN

This randomized, double-blind, placebo-controlled trial will evaluate whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants will receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, resting metabolic rate, metabolic measures, and whole-body quantitative computed tomography. An optional mechanistic substudy of up to 36 participants will include D3-creatine dilution, nonradioactive stable isotope infusions, repeated blood sampling, a standardized meal, breath sampling, and vastus lateralis muscle biopsies at baseline and month 6.

Phase 2
Waitlist Available

Vanderbilt University Medical Center

Robb Flynn, PhD

Have you considered Nesina clinical trials?

We made a collection of clinical trials featuring Nesina, we think they might fit your search criteria.
Go to Trials